Get the Stockscreener App
7.99
0.62%
-0.05
Pre-market:
8.08
0.09
+1.13%
Cybin Inc stock is traded at $7.99, with a volume of 256.33K.
It is down -0.62% in the last 24 hours and down -3.27% over the past month.
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
See More
Previous Close:
$8.04
Open:
$8
24h Volume:
256.33K
Relative Volume:
0.73
Market Cap:
$183.96M
Revenue:
-
Net Income/Loss:
$-52.07M
P/E Ratio:
-38.47
EPS:
-0.2077
Net Cash Flow:
$-44.93M
1W Performance:
-3.97%
1M Performance:
-3.27%
6M Performance:
-20.34%
1Y Performance:
-26.33%
1-Day Range:
$7.80
$8.0699
1-Week Range:
$7.55
$8.84
52-Week Range:
$4.81
$13.88
Cybin Inc Stock (CYBN) Company Profile
Name
Cybin Inc
Sector
Industry
Phone
908 764 8385
Address
100 King Street West, Suite 5600, Toronto
Compare CYBN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
7.99 | 185.19M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Stock (CYBN) Latest News
What are analysts’ price targets for Cybin Inc. in the next 12 monthsInvest confidently with real-time data analysis - jammulinksnews.com
Why is Cybin Inc. stock attracting strong analyst attentionMaximize your portfolio’s growth potential - jammulinksnews.com
When is Cybin Inc. stock expected to show significant growthPre Market Trend Scanner With High Returns - jammulinksnews.com
What are Cybin Inc. company’s key revenue driversAchieve rapid wealth accumulation through smart investing - jammulinksnews.com
Is Cybin Inc. stock overvalued or undervaluedConsistently superior profits - jammulinksnews.com
What institutional investors are buying Cybin Inc. stockAchieve consistent returns with proven methods - jammulinksnews.com
What are the technical indicators suggesting about Cybin Inc.Access high-yield investment alerts now - jammulinksnews.com
What is the dividend policy of Cybin Inc. stockInvest smarter with daily market updates - jammulinksnews.com
Should I hold or sell Cybin Inc. stock in 2025Extraordinary performance - jammulinksnews.com
How Cybin Inc. stock performs during market volatilitySolid Return Trade Selections - Metal.it
What analysts say about Cybin Inc. stockSuperior portfolio returns - PrintWeekIndia
Cybin Inc. Stock Analysis and ForecastFree Capital Efficiency Planning - PrintWeekIndia
Is Cybin Inc. a good long term investmentExceptional growth trajectory - PrintWeekIndia
Cybin, Inc: CYB003 Vs. GH001Duration, Durability and Protocol Execution - Smartkarma
What drives Cybin Inc. stock pricePowerful market insights - PrintWeekIndia
Will Cybin Inc. stock benefit from AI tech trendsFree Predictions - jammulinksnews.com
I can have 5% loss. - AInvest
(CYBN) Proactive Strategies - news.stocktradersdaily.com
High-Risk, High-Reward Stocks With Serious Momentum: 5 Stocks to Consider - AInvest
Cybin Inc: CYB003 Phase 3 Program Continues to Progress on Plan - Smartkarma
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Don't Trip. These Psychedelic Stocks May Have Some Life in Them Yet - US News Money
Wall Street Analysts See an 831.44% Upside in Cybin Inc. (CYBN): Can the Stock Really Move This High? - Yahoo Finance
UK MHRA approves Cybin’s trial of CYB003 for major depressive disorder - Yahoo Finance
Three High-Risk, High-Reward Stocks in AI, Biotech, and Autonomous Vehicles - AInvest
Cybin's EMBRACE Study: A Pivotal Step in Psychedelic-Driven Mental Healthcare Innovation - AInvest
Cybin receives UK MHRA approval to commence EMBRACE study - TipRanks
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Cybin Secures UK Approval for Pivotal Depression Study - TipRanks
Cybin receives UK approval for second pivotal depression study By Investing.com - Investing.com South Africa
Cybin receives UK approval for second pivotal depression study - Investing.com
Cybin Inc Stock (CYBN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Cap:
|
Volume (24h):